Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02679573 · ClinicalTrials.gov registry record · Phase 3
Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
A Phase 3 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 860
- Enrollment target
NCT02679573 is a Phase 3 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 860 participants.
The verdict
NCT02679573, a Phase 3 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 860 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of delafloxacin compared to moxifloxacin in the treatment of adult patients with community-acquired pneumonia.
Interventions
- DRUG Moxifloxacin
- DRUG Linezolid
- DRUG Delafloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2016-12-14 |
| Est. Completion | 2018-08-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02679573
The ClinicalTrials.gov registry entry for NCT02679573 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 860 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Moxifloxacin is the first listed.
NCT02679573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02679573 about?
NCT02679573 is a clinical study titled "Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia". The purpose of this study is to evaluate the safety and efficacy of delafloxacin compared to moxifloxacin in the treatment of adult patients with community-acquired pneumonia.
What is the current status of trial NCT02679573?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 860 participants. The study started on 2016-12-14. Estimated completion is 2018-08-07.
What interventions are being tested in trial NCT02679573?
The interventions under investigation include: Moxifloxacin (DRUG), Linezolid (DRUG), Delafloxacin (DRUG).
Who is sponsoring clinical trial NCT02679573?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.